The emergence of drug-resistant tuberculosis in New York City
about
Purification of a novel coenzyme F420-dependent glucose-6-phosphate dehydrogenase from Mycobacterium smegmatisTuberculosis control: challenges of an ancient and ongoing epidemicTranslating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosisStructural and functional analysis of the transcriptional regulator Rv3066 of Mycobacterium tuberculosisCrystal structure of the transcriptional regulator Rv1219c ofMycobacterium tuberculosisCrystal Structure of the Transcriptional Regulator Rv0678 of Mycobacterium tuberculosisFluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophagesIn vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugsSynergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosisMoxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosisAlterations in macromolecular composition and cell wall integrity by ciprofloxacin in Mycobacterium smegmatisCan penicillins and other beta-lactam antibiotics be used to treat tuberculosis?In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosisFluoroquinolone action in mycobacteria: similarity with effects in Escherichia coli and detection by cell lysate viscosityIn vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosisWhich aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic reviewPurification and characterization of recombinant catalase-peroxidase, which confers isoniazid sensitivity in Mycobacterium tuberculosisOverexpression, purification, and characterization of the catalase-peroxidase KatG from Mycobacterium tuberculosisIsoniazid-resistant cavitary tuberculosis in a physician following isoniazid prophylaxis.Evaluation and utilization as a public health tool of a national molecular epidemiological tuberculosis outbreak database within the United Kingdom from 1997 to 2001Drug Resistance Pattern of MTB Isolates from PTB PatientsMatching AIDS and tuberculosis registry data to identify AIDS/tuberculosis comorbidity cases in California.Assessing the validity of tuberculosis surveillance data in California.Drug-resistant tuberculosis: a worldwide epidemic poses a new challengeAIDS and the lung: update 1995. 2. New developments in the pulmonary diseases affecting HIV infected individuals.Pulmonary complications of HIV disease: 10 year retrospective evaluation of yields from bronchoalveolar lavage, 1983-93.Isolation of anti-mycobacterial compounds from Curtisia dentata (Burm.f.) C.A.Sm (Curtisiaceae).Three-dimensional model and molecular mechanism of Mycobacterium tuberculosis catalase-peroxidase (KatG) and isoniazid-resistant KatG mutantsMortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia.Tuberculosis and HIV infection. How to safely treat both disorders concurrently.Prevention and management of tuberculosis in HIV positive patients living in countries with a low prevalence of Mycobacterium tuberculosis.The susceptibility of Mycobacterium tuberculosis to isoniazid and the Arg-->Leu mutation at codon 463 of katG are not associated.Detection of rifampin-resistant Mycobacterium tuberculosis in sputa by nested PCR-linked single-strand conformation polymorphism and DNA sequencing.Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing.Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru.TB across the globe (5). The USA experience.Drug-resistant Mycobacterium tuberculosis in California, 1991 to 1992.Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat.Medicaid policies for HIV-related prescription drugs.
P2860
Q24683754-8E4308C4-73E6-4EEE-A902-665EA370D014Q26206908-1BADEEDF-5A04-4A1F-8741-8D5A5481E6F8Q26824812-7F526B66-7A5C-4330-8D46-2448A2E20E29Q27670866-E4FE18E6-CB2C-43C3-9C65-7801E819D030Q27681336-C9020CF9-09A8-44DE-800B-6BB19914C231Q27683409-94FF0752-5660-480B-BDFC-A08F1A370275Q28343182-C178CD0D-5347-48E2-B0BC-80C7DA992B1BQ28344608-213C0D03-9BE3-42BF-A609-59A56188339BQ28367457-19EBCD7E-34B6-474E-B3A4-9266BA44CCDEQ28369466-4D48A4B0-E7F0-4B64-8536-616402FCA387Q28373280-4C340E08-BA17-479F-8801-F4781C275495Q28378791-A0051480-7ACA-4ED2-8AAA-07160B3F6D78Q28378826-46F21CC2-2A8A-4FC8-8DC6-2D224766E72CQ28379135-8F309F83-BD5C-437B-99D7-F2137E627BADQ28379137-2932BEBA-CBDB-4CE9-89CD-BB487390F5A6Q28379500-8FFA074C-5CEC-4142-B17E-5637F910176FQ28475509-790B12B2-1114-4C25-9E84-A4F46D1A63B3Q28486593-D3A0673E-44B8-4532-8769-84826629A2CBQ28486741-1DD3545E-EFC0-48A8-81C0-7747A70209CBQ30310172-F9DF13FE-C899-43EA-8AD6-468944931610Q30332824-AB8842AB-5865-4DF3-A1F3-2E2A0063C97AQ30356107-52DEDED7-18EE-44E5-97FB-69E3A064A304Q30843408-930630D2-7091-44A1-AFC8-0C7BA5964830Q33255129-7DA72772-1E9F-4D60-82C5-DD76C7774537Q33595284-91E2A8E9-461F-4FD8-AB54-D0106BEB9F6BQ33604838-C0268971-3FBA-4139-AFC8-5C7EB5F18BF4Q33605240-809C6A41-A573-42EF-B05A-1ED247D8C6A4Q33791853-1DD2D0D3-DB87-4EC6-8C17-C48F19A5F553Q33832195-89E5E2D7-FB8A-4493-B4B9-07ACC890BCCCQ33901443-8431B133-BFCD-4B15-AD4D-FCEFFBED5F09Q33914717-293D6E91-AE18-446F-BD4D-A553E9F27005Q33936003-98E4615A-A93C-4062-A65F-3B30A5B43144Q33972028-AA44F9B0-305D-43ED-ADCB-A8F1917642CFQ33972943-2415C51C-C33E-4686-9487-D3CB952C8510Q33978473-B99DE3A1-4668-4700-8DA6-1E4E392D6CFEQ34030008-2A89B279-1FD6-4F56-A549-5DAADB96BFD1Q34113898-D1029E64-A95C-4680-B96A-418F413AD54AQ34182134-98D0C461-A180-44EE-9C04-8E42A991C4DFQ34218737-9A95407F-A7F3-487E-9AA9-7EAC020F7653Q34321740-CB47C589-5F60-406E-AD37-50A2CEF3D8A7
P2860
The emergence of drug-resistant tuberculosis in New York City
description
1993 nî lūn-bûn
@nan
1993 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
name
The emergence of drug-resistant tuberculosis in New York City
@ast
The emergence of drug-resistant tuberculosis in New York City
@en
The emergence of drug-resistant tuberculosis in New York City
@nl
type
label
The emergence of drug-resistant tuberculosis in New York City
@ast
The emergence of drug-resistant tuberculosis in New York City
@en
The emergence of drug-resistant tuberculosis in New York City
@nl
prefLabel
The emergence of drug-resistant tuberculosis in New York City
@ast
The emergence of drug-resistant tuberculosis in New York City
@en
The emergence of drug-resistant tuberculosis in New York City
@nl
P2093
P3181
P1476
The emergence of drug-resistant tuberculosis in New York City
@en
P2093
A Pablos-Mendez
G M Cauthen
J O Kilburn
S W Dooley
T R Frieden
T Sterling
P3181
P356
10.1056/NEJM199302253280801
P407
P577
1993-02-25T00:00:00Z